Aristides Capital’s KalVista Pharmaceuticals KALV Stock Holding History

Aristides Capital’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-12,000	Closed	-$174K	–	259
2022 Q3	$174K	Sell	12,000 -11,000	-48%	-$154K	0.13%	123
2022 Q2	$226K	Hold	23,000	–	–	0.15%	115
2022 Q1	$339K	Hold	23,000	–	–	0.21%	109
2021 Q4	$304K	Hold	23,000	–	–	0.14%	135
2021 Q3	$401K	Hold	23,000	–	–	0.15%	103
2021 Q2	$551K	Buy	+23,000	New	+$602K	0.13%	84

Other funds holding KALV

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Aristides Capital's KALV Position: Q4 2022 in Review

Aristides Capital sold out of KalVista Pharmaceuticals (KALV) in Q4 2022, closing a stake of 12,000 shares — an estimated $174K sold.

Aristides Capital first reported a position in KALV in Q2 2021 and held it in 6 quarters. The position peaked at $551K in Q2 2021. 91 funds tracked by Wall St. Rank hold KALV as of Q4 2022.

Aristides Capital reported no remaining KalVista Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Aristides Capital sold 12,000 KalVista Pharmaceuticals shares in Q4 2022, an estimated $174K.
Aristides Capital first reported a position in KalVista Pharmaceuticals in Q2 2021 and held it in 6 quarters.
Aristides Capital's KalVista Pharmaceuticals position peaked at $551K in Q2 2021.
91 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2022.

Based on Aristides Capital's 13F filing for Q4 2022, filed 14 Feb 2023.